PROFUSA, INC. Research and Development Expense
PROFUSA, INC. (PFSA) reported Research and Development Expense of $823.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-19
- PROFUSA, INC. research and development expense for the quarter ending 2026-06-30 was $823.00K, a 109.41% increase year-over-year.
- PROFUSA, INC. research and development expense for the quarter ending 2026-03-31 was $1.15M, a 164.06% increase year-over-year.
- PROFUSA, INC. research and development expense for the quarter ending 2025-12-31 was $1.25M, a 384.56% increase year-over-year.
- PROFUSA, INC. research and development expense for the quarter ending 2025-09-30 was $722.00K, a 75.67% increase year-over-year.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $823.00K 10-Q · filed 2026-08-19 | $1.97M 10-Q · filed 2026-08-19 | $3.22M derived: sum of 3 quarters · filed 2026-08-19 | $3.95M derived: sum of 4 quarters · filed 2026-08-19 |
| 2026-03-31 | $1.15M 10-Q · filed 2026-05-15 | $2.40M derived: sum of 2 quarters · filed 2026-05-15 | $3.12M derived: sum of 3 quarters · filed 2026-05-15 | $3.52M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-12-31 | $1.25M derived: S-1/A 12 month − 10-Q 9 month · filed 2026-05-01 | $1.98M derived: sum of 2 quarters · filed 2026-05-01 | $2.37M derived: sum of 3 quarters · filed 2026-08-19 | $2.80M S-1/A · filed 2026-05-01 |
| 2025-09-30 | $722.00K 10-Q · filed 2025-11-19 | $1.11M derived: sum of 2 quarters · filed 2026-08-19 | $1.55M 10-Q · filed 2025-11-19 | $1.81M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-06-30 | $393.00K 10-Q · filed 2026-08-19 | $827.00K 10-Q · filed 2026-08-19 | $1.09M derived: sum of 3 quarters · filed 2026-08-19 | $1.50M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-03-31 | $434.00K 10-Q · filed 2026-05-15 | $693.00K derived: sum of 2 quarters · filed 2026-05-15 | $1.10M derived: sum of 3 quarters · filed 2026-05-15 | |
| 2024-12-31 | $259.00K derived: S-1/A 12 month − 10-Q 9 month · filed 2026-05-01 | $670.00K derived: sum of 2 quarters · filed 2026-05-01 | $1.61M S-1/A · filed 2026-05-01 | |
| 2024-09-30 | $411.00K 10-Q · filed 2025-11-19 | $1.35M 10-Q · filed 2025-11-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |